BridgeBio Pharma, Inc. (BBIO)

業務介紹

BridgeBio Pharma, Inc.（BridgeBio Pharma股份有限公司）從事發現、開發和提供各種遺傳疾病藥物。該公司擁有30個開發計劃，包括從早期發現到後期開發的產品候選藥物。其開發計劃中的產品包括AG10和BBP-265，這是一種小分子產物，用於穩定甲狀腺素轉運蛋白（TTR），目前正在進行第3期臨床試驗，用於治療TTR淀粉樣變-心肌病（ATTR-CM）；BBP-831是一種小分子選擇性FGFR1-3抑制劑，目前正在進行第2期臨床試驗，用於治療小兒成骨不全症；BBP-631是一種AAV5基因轉移產品候選藥物，目前正在進行第2期臨床試驗，用於治療由21-羥化酶缺乏引起的先天性腎上腺增生症（CAH）。該公司還開發了Encaleret，這是一種鈣感受受體（CaSR）的小分子拮抗劑，目前正在進行第2期概念驗證臨床試驗，用於治療常染色體顯性低鈣血症1型（ADH1）；以及BBP-711，用於治療高草酸尿症和反復腎結石患者。此外，該公司還從事孟德爾遺傳學、腫瘤學和基因治療疾病的產品開發。BridgeBio Pharma, Inc.與Leland Stanford Junior University、The Regents of the University of California和Leidos Biomedical Research, Inc.簽訂了許可和合作協議。該公司成立於2015年，總部位於加利福尼亞州帕洛阿爾托。

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

公司網址

https://www.bridgebio.com